Literature DB >> 8517787

On the enzyme-inducing action of calcium antagonists.

M Koleva1, T Stoytchev.   

Abstract

The effects of three calcium antagonists, nifedipine (NF), verapamil (V) and diltiazem (DL), on rat liver monooxygenases were studied. The drugs were administered in oral doses of 50, 40 and 30 mg/kg daily for 3 weeks in male Wistar rats. NF and V shortened the hexobarbital (HB) sleeping time and increased benzphetamin-N-demethylase (BND), ethylmorphine-N-demethylase (EMND), aniline hydroxylase (AH), ethoxycoumarine-O-deethylase (ECOD), ethoxyresorufin-O-deethylase (EROD) and NADPH-cytochrome c reductase activities and the content of cytochrome P-450 and microsomal heme, but did not change the content of cytochrome b5. The data suggest that these calcium antagonists exert an enzyme-inducing effect on the hepatic monooxygenases. DL significantly increased only the EROD and NADPH-cytochrome c reductase activities and shortened HB sleeping time to a lesser extent, suggesting a weaker enzyme-inducing effect as compared to NF and V. The three drugs increased the delta-aminolevulinic acid (ALA) synthetase activity and decreased heme oxygenase (HO) activity. The increased cytochrome P-450 content is probably due to the increased synthesis and the decreased breakdown of this hemoprotein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517787     DOI: 10.1007/BF01974350

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  17 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Induction of cytochrome P-450 isozymes upon repeated administration of nifedipine.

Authors:  M Koleva; T Stoytchev; L Gulyaeva; A Grishanova; V Mishin; V Lyakhovich
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Apr-Jun       Impact factor: 2.441

Review 3.  [The role of Ca2+ in the pathogenesis of epilepsy. Calcium antagonists--a new class of anticonvulsants].

Authors:  R N Glebov; M N Karpova
Journal:  Patol Fiziol Eksp Ter       Date:  1990 May-Jun

4.  Experimental antiarteriosclerotic effects of calcium antagonists.

Authors:  A Fleckenstein; G Fleckenstein-Grün; M Frey; F Thimm
Journal:  J Clin Pharmacol       Date:  1990-02       Impact factor: 3.126

5.  The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase.

Authors:  R Tenhunen; H S Marver; R Schmid
Journal:  Proc Natl Acad Sci U S A       Date:  1968-10       Impact factor: 11.205

6.  Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

Authors:  F P Guengerich; W R Brian; M Iwasaki; M A Sari; C Bäärnhielm; P Berntsson
Journal:  J Med Chem       Date:  1991-06       Impact factor: 7.446

7.  Liver monooxygenase activity after multiple application of nifedipin, verapamil and diltiazem.

Authors:  M Koleva; T Stoytchev
Journal:  Acta Physiol Pharmacol Bulg       Date:  1990

8.  Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.

Authors:  K W Renton
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

9.  Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem.

Authors:  L Pichard; G Gillet; I Fabre; I Dalet-Beluche; C Bonfils; J P Thenot; P Maurel
Journal:  Drug Metab Dispos       Date:  1990 Sep-Oct       Impact factor: 3.922

10.  Calcium, its agonists and antagonists: past, present and future.

Authors:  R M Jones
Journal:  J R Soc Med       Date:  1987-03       Impact factor: 18.000

View more
  1 in total

1.  Induction of heme oxygenase-1 and heat shock protein 70 in rat hepatocytes: the role of calcium signaling.

Authors:  Malte Silomon; Inge Bauer; Michael Bauer; Julia Nolting; Markus Paxian; Hauke Rensing
Journal:  Cell Mol Biol Lett       Date:  2006-11-13       Impact factor: 5.787

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.